Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of metastatic cancer
• Tumor overexpresses p53 as assessed by immunohistochemistry (i.e., ≥ 5% tumor cells stain positive for p53)
• * Biopsy must be available to evaluate p53 expression
• Human leukocyte antigens 0201 (HLA-A\*0201) positive
• Progressive or recurrent disease after prior standard therapy for metastatic disease
• * Patients with melanoma or renal cell cancer must have previously received aldesleukin
• * Patients with other histologies, not including hematologic malignancies, must have previously received first-line and second-line or higher systemic standard therapy (or effective salvage chemotherapy regimens)
• PATIENT CHARACTERISTICS:
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Life expectancy \> 3 months
• Absolute neutrophil count \> 1,000/mm\^3
• White blood cell (WBC) \> 3,000/mm\^3
• Platelet count \> 100,000/mm\^3
• Hemoglobin \> 8.0 g/dL
• Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 2.5 times upper limit of normal
• Serum creatinine ≤ 1.6 mg/dL
• Total bilirubin ≤ 2.0 mg/dL (\< 3.0 mg/dL in patients with Gilbert's syndrome)
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 4 months after completion of study treatment
• Patients who have previously received ipilimumab or ticilimumab must have a normal colonoscopy with normal colonic biopsies
• Human immunodeficiency virus (HIV) antibody negative
• Hepatitis B antigen and hepatitis C antibody negative (unless antigen negative)
• No primary immunodeficiency (e.g., severe combined immunodeficiency disease)
• No active systemic infections
• No history of severe immediate hypersensitivity reaction to any of the agents used in this study
• No coagulation disorders
• No myocardial infarction or cardiac arrhythmias
• No history of coronary revascularization
• No obstructive or restrictive pulmonary disease
• No contraindications for high-dose aldesleukin administration
• Left ventricular ejection fraction (LVEF) ≥ 45% in patients meeting any of the following criteria:
• * History of ischemic heart disease,
• * chest pain,
• * or clinically significant atrial and/or ventricular arrhythmias including, but not limited to, atrial fibrillation,
• * ventricular tachycardia,
• * or second- or third-degree heart block
• * At least 60 years of age
• Forced expiratory volume 1 (FEV\_1) \> 60% predicted in patients meeting any of the following criteria:
• * Prolonged history of cigarette smoking (\> 20 pack/year within the past 2 years)
• * Symptoms of respiratory dysfunction
• No other major medical illness of the cardiovascular,
• * respiratory,
• * or immune system
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Recovered from prior therapy
• More than 4 weeks since prior and no concurrent systemic steroid therapy
• More than 4 weeks since other prior systemic therapy
• More than 6 weeks since prior ipilimumab